and when the comparison between the arms fails tries to get approved based on post hoc endpoints against historical comps.
objection speculation you dont know it failed! you are saying that but you dont have any prove it did
and again so the EMA/UK is nuts accepting new endpoints?
I have never understood your reproach of NWBO not continuing patients in the control arm so the stats can be better compared alas they must die in doing so.
Market Data 
Markets 
AI
